HPHéctor Juan Prado

Héctor Juan Prado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Héctor Juan Prado has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Ángeles Gloria Rodríguez-Basso

    Universidad de Buenos Aires, Facultad de Farmacia y Bioquímica, Cátedra de Farmacología, Junín 956, Buenos Aires C1113AAD, Argentina

    2 shared publications
  • Adriana Fernández

    Pharmaceutical Technology Department, Faculty of Pharmacy and Biochemistry, Universidad de Buenos Aires, Junín 956, Buenos Aires C1113AAD, Argentina

    1 shared publication
  • Aldo Roberto Boccaccini

    Institute of Biomaterials University of Erlangen‐Nuremberg Erlangen Germany

    1 shared publication
  • Carlos A Sandrone

    Facultad de Farmacia y Bioquímica, Departamento de Tecnología Farmacéutica, Cátedra de Tecnología Farmacéutica II, Universidad de Buenos Aires , C1113AAD Buenos Aires

    1 shared publication
  • Christian Höcht

    Facultad de Farmacia y Bioquímica, Departamento de Farmacología, Universidad de Buenos Aires , C1113AAD Buenos Aires

    1 shared publication
  • Daniel R Vega

    Departamento Física de la Materia Condensada, Gerencia de Investigación y Aplicaciones, Centro Atómico Constituyentes, Comisión Nacional de Energía Atómica y Escuela de Ciencia y Tecnología, Universidad Nacional General San Martín , B1650KNA San Martín

    1 shared publication

Latest Publications

  • Open Access

    Critical Attribute Considerations in Designing Systems for Sustained Topical Delivery of Hydrophobic Drugs for the Treatment of Acne Vulgaris

    by María Eugenia Acevedo, Judith Anna Roether, Sofía Harriet, Adriana Fernández, Juan Pablo Cattalini, Héctor Juan Prado, Aldo R. Boccaccini, Viviana Mouriño

    Background/Objectives: A matrix system for topical application was developed for a hydrophobic drug model, benzoyl peroxide (BPO), by turning it into its amorphous state to increase its bioavailability. BPO is commonly used to treat acne vulgaris; however, the commercially available products possess several drawbacks including poor absorption due to large crystal size and thus reduced efficacy and skin irritation. Methods: Several polymeric films containing amorphous BPO were successfully prepared for the first time from polymer + plasticizer colloidal dispersions and characterized. Results: The loaded BPO maintained its amorphous state even after 24 months of storage at 5 °C, and drug release could be modulated by adjusting the film compositions. The prepared films were obtained by solvent evaporation, and residual acetone remained below the level of quantification of the analytical method. In addition, the films were thin, flexible, transparent, bioadhesive, and able to remain on the skin for a clinically relevant period. Microscopic imaging confirmed a homogeneous and continuous morphology. Conclusions: The developed formulations may represent promising alternatives for the treatment of acne vulgaris.

  • Open Access

    Chemical Profile and In Vitro Protective Effects of Minthostachys verticillata (Griseb.) Epling Aqueous Extract in Intestinal Inflammatory Environments

    by Angeles Gloria Rodríguez-Basso, Héctor Juan Prado, María Cristina Matulewicz, Karen Perelmuter, Romina Pagotto, Hernán Bach, Susana Beatriz Gorzalczany, Mariela Bollati-Fogolín

    Minthostachys verticillata (Griseb.) Epling, commonly known as peperina, is an aromatic species endemic to Argentina and traditionally used for gastrointestinal ailments. Despite its extensive folkloric use and inclusion in the Argentine Pharmacopoeia, its aqueous extract (the most commonly consumed preparation) has been described in terms of major phytochemical groups, and, currently, no studies have investigated its effects on key intestinal epithelial mechanisms. This plant is also employed in the production of beverages and herbal blends, and its massive consumption highlights the importance of its scientific study. Here, the aqueous extract of M. verticillata was characterized by liquid chromatography–tandem mass spectrometry, leading to the identification of fourteen polyphenolic compounds. In intestinal cell models, the extract displayed high IC50 values, supporting its safety, and exhibited concentration-dependent bioactivity. In HT-29 cells, it modulated NF-κB activation induced by TNF-α and reduced LPS-stimulated IL-8 production. Pretreatment of Caco-2 monolayers prevented the decrease in transepithelial electrical resistance, increased FITC–dextran permeability, and nitric oxide production triggered by an inflammatory cocktail. Additionally, the extract inhibited HT-29 cell migration. These results demonstrate that M. verticillata aqueous extract exerts anti-inflammatory, barrier-protective, and anti-migratory effects in vitro, providing novel insights into how its polyphenolic composition may underlie these biological activities, supporting its traditional use and potential applications in intestinal health.


  • Development of benznidazole orally disintegrating tablets for paediatric patients

    by Fermín Cañete Alberdi, María F Filia, Laura D Simionato, Carlos A Sandrone, Daniel R Vega, Javier Oppezzo, Christian Höcht, Diego A Chiappetta, Viviana S L Mouriño, Héctor J Prado

    Objectives: To develop the orphan drug benznidazole (BNZ) in orally disintegrating tablets, for the neglected disease American Trypanosomiasis (Chagas disease) therapy. Although children are highly affected by this disease, there are no specific commercial pharmaceutical preparations for this age group in Argentina and in many other countries. Methods: In the production process, co-milling in a ball mill was applied to enhance dissolution rates, followed by direct compression. Taste preference and taste masking experiments were conducted in a test panel of adult volunteers. The tablets were fully characterized and their stability and bioavailability determined. Key findings: The tablets complied with all the quality control prerequisites, their disintegration time was 30 s, and as a consequence of the intimate mixture with hydrophilic excipients and particle size reduction, BNZ dissolution was improved, reaching 75% in 0.1 N hydrochloric acid and 62% in simulated salivary fluid, after 5 min. X-ray diffraction studies showed that BNZ maintained its original crystalline state (form I) in the tablets. The ODTs remained stable for at least 1 year. Oral bioavailability of BNZ of suspensions obtained from the prepared ODTs was comparable with that of pulverized commercial tablets. Conclusions: The developed tablets may improve paediatric Chagas disease therapeutics.

  • Concurrent Determination of Pridinol, Diclofenac and Impurity A by HPLC-UV

    by Ángeles Gloria Rodríguez-Basso, Silvina Laura Bonafede, Héctor Juan Prado

    A reversed-phase high-performance liquid chromatography method was developed and validated for the simultaneous determination of pridinol, diclofenac and diclofenac-related compounds in tablet formulations. The proposed method is also suitable for content uniformity determination, for dissolution test and for stability studies. Separation was achieved on a base-deactivated silica C8 column, using 50 mM phosphate buffer (pH 2.5) and methanol (40:60 v/v) as mobile phase, at a flow rate of 1.0 mL/min and column temperature of 40°C. Ultraviolet detection was made at 225 nm. The method was validated for specificity, accuracy, precision (intraday and interday levels) and linearity for each analyte. For diclofenac impurity A, sensitivity was also studied. The method showed specificity and linearity (R2: 0.999 for the three analytes) over the assessed concentration range (diclofenac: 2.5–75.0 μg/mL, pridinol: 2.0–60.0 μg/mL and impurity A: 1.25–5.0 μg/mL) and demonstrated good precision as reflected by the low coefficient of variation in all cases. Recovery rates obtained were 99.81, 100.58 and 100.96% for diclofenac, pridinol and impurity A respectively, and for all three analytes, the variances of the concentrations tested were equivalent. The detection and quantitation limits for impurity A were 0.078 and 0.261 μg/mL, respectively.